Innovation and growth should drive several biotech and drug stocks higher in 2020, despite political risk around drug pricing, according to Mizuho.
"Overall, we are bullish on the biopharma sector mainly because of the remarkable innovation we are seeing, including in areas such as neuroscience where innovation has historically been tougher to come by," Mizuho said in a note to clients.
Россия Последние новости, Россия Последние новости
Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей
Источник: BusinessInsider - 🏆 729. / 51 Прочитайте больше »